10/061,128

FILE 'HOME' ENTERED AT 10:46:35 ON 14 NOV 2003

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 0.21 — TOTAL SESSION: 0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 10:46:51 ON 14 NOV 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 10:46:51 ON 14 NOV 2003

FILE 'CAPLUS' ENTERED AT 10:46:51 ON 14 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:46:51 ON 14 NOV 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 10:46:51 ON 14 NOV 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s treatment (4a) hepatitis and 2 fluoro (3w) nucleoside?
L1 15 TREATMENT (4A) HEPATITIS AND 2 FLUORO (3W) NUCLEOSIDE?

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 14 DUP REM L1 (1 DUPLICATE REMOVED)

=> s l2 and human
L3 10 L2 AND HUMAN

=> d l3 bib abs 1-10

L3 ANSWER 1 OF 10 USPATFULL on STN
AN 2003:127658 USPATFULL
TI Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
IN Stuyver, Lieven, Snellville, GA, UNITED STATES
Watanabe, Kyoichi, Stone Mountain, GA, UNITED STATES
PI US 2003087873 A1 20030508
AI US 2001-45292 A1 20011018 (10)
PRAI US 2000-241488P 20001018 (60)
US 2001-282156P 20010406 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 6390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug.

This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction ("RT-PCR"). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 10 USPATFULL on STN
AN 2003:120823 USPATFULL
TI Anti-HCV nucleoside derivatives
IN Devos, Rene Robert, Welwyn Garden City, UNITED KINGDOM
Hobbs, Christopher John, Hertford, UNITED KINGDOM
Jiang, Wen-Rong, Welwyn Garden City, UNITED KINGDOM
Martin, Joseph Armstrong, Harpenden, UNITED KINGDOM
Merrett, John Herbert, Baldock, UNITED KINGDOM
Najera, Isabel, St. Albans, UNITED KINGDOM
PI US 2003083307 A1 20030501
AI US 2002-106970 A1 20020326 (10)
PRAI GB 2001-12617 20010523
DT Utility
FS APPLICATION
LREP HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises nucleoside derivatives for use in the **treatment** or prophylaxis of **hepatitis** C virus infections. In particular, the present invention discloses the novel use of known 2'-deoxy-**2**'-**fluoro nucleoside** derivatives as inhibitors of hepatitis C virus (HCV) RNA replication and pharmaceutical compositions of such compounds. The compounds of this invention have potential use as therapeutic agents for the treatment of HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 10 USPATFULL on STN
AN 2003:87014 USPATFULL
TI Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides
IN Sznaidman, Marcos, Durham, NC, UNITED STATES
PI US 2003060622 A1 20030327
AI US 2002-112403 A1 20020329 (10)
PRAI US 2001-280307P 20010330 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to the process for the preparation of 2'-deoxy-2'-halo-.beta.-L-arabinofuranosyl nucleosides, and in particular, 2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is commercially available and less expensive than L-ribose or L-xylose, in ten steps. All of the reagents

09567863

and starting materials are inexpensive and no special equipment is required to carry out the reactions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 10 USPATFULL on STN
AN 2002:344441 USPATFULL
TI 2'-fluoronucleosides
IN Schinazi, Raymond F., Decatur, GA, UNITED STATES
Liotta, Dennis C., McDonough, GA, UNITED STATES
Chu, Chung K., Athens, GA, UNITED STATES
McAtee, J. Jeffrey, Mobile, AL, UNITED STATES
Shi, Junxing, Decatur, GA, UNITED STATES
Choi, Yongseok, Athens, GA, UNITED STATES
Lee, Kyeong, Athens, GA, UNITED STATES
Hong, Joon H., Athens, GA, UNITED STATES
PI US 2002198171 A1 20021226
AI US 2002-61128 A1 20020130 (10)
RLI Continuation of Ser. No. US 1999-257130, filed on 25 Feb 1999, GRANTED, Pat. No. US 6348587
PRAI US 1998-75893P 19980225 (60)
US 1998-80569P 19980403 (60)
DT Utility
FS APPLICATION
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A class of **2'-fluoro-nucleoside** compounds are disclosed which are useful in the **treatment** of **hepatitis** B infection, **hepatitis** C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: ##STR1##

wherein

Base is a purine or pyrimidine base;

R.sup.1 is OH, H, OR.sup.3, N.sub.3, CN, halogen, including F, or CF.sub.3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;

R.sup.2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R.sup.2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and

R.sup.3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 10 USPATFULL on STN

09567863

AN 2002:106274 USPATFULL
TI 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections
IN Watanabe, Kyoichi A., Stone Mountain, GA, UNITED STATES
Pai, S. Balakrishna, Chamblee, GA, UNITED STATES
PI US 2002055483 A1 20020509
AI US 2001-834596 A1 20010413 (9)
PRAI US 2000-197068P 20000413 (60)
US 2000-202663P 20000508 (60)
DT Utility
FS APPLICATION
LREP TROUTMAN SANDERS LLP, BANK OF AMERICA PLAZA, SUITE 5200, 600 PEACHTREE STREET , NE, ATLANTA, GA, 30308-2216
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas [I]- [IV] below and mixtures of two or more thereof: ##STR1##

wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 10 USPATFULL on STN
AN 1998:112111 USPATFULL
TI L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
IN Chu, Chung K., Athens, GA, United States
Cheng, Yung-Chi, Woodbridge, CT, United States
Pai, Balakrishna S., New Haven, CT, United States
Yao, Gang-Qing, Guilford, CT, United States
PA Yale University, New Haven, CT, United States (U.S. corporation)
The University of Georgia Research Foundation, Inc., Athens, GA, United States (U.S. corporation)
PI US 5808040 19980915
WO 9520595 19950803
AI US 1997-682623 19970124 (8)
WO 1995-US1253 19950130
19970124 PCT 371 date
19970124 PCT 102(e) date
DT Utility
FS Granted
EXNAM Primary Examiner: Wilson, James O.
LREP Knowles, Sherry M., Haley, JacquelineKing & Spalding
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for stabilizing an oligonucleotide by including a .beta.-L-2'-deoxy-**2**'-**fluoro**-arabinofuranosyl **nucleoside** at the 5'-terminus, the 3'-terminus, or in the interior of the oligonucleotide. The oligonucleotide can be used in the modulation of gene expression through a process wherein a synthetic

oligonucleotide is hybridized to a complementary nucleic acid sequence to inhibit transcription or replication of DNA or to inhibit translation or processing of RNA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 10 USPATFULL on STN
AN 1998:55028 USPATFULL
TI Oligonucleotides containing L-nucleosides
IN Chu, Chung K., Athens, GA, United States
Cheng, Yung-Chi, Woodbridge, CT, United States
Pai, Balakrishna S., New Haven, CT, United States
Yao, Gang-Qing, Guilford, CT, United States
PA Yale University, New Haven, CT, United States (U.S. corporation)
University of Georgia Research Found., Athens, GA, United States (U.S. corporation)
PI US 5753789 19980519
AI US 1996-690350 19960726 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Kunz, Gary L.
LREP Knowles, Esq., Sherry M.King & Spalding
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1728
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Oligonucleotides that include a **2'-fluoro** .beta.-L-arabinofuranosyl **nucleoside** at the 3'-terminus, the 5'-terminus or in the interior of the oligomer. A preferred nucleoside is 2'-fluoro-5-methyl-.beta.-L-arabinofuranosyluridine (also referred to as L-FMAU). This compound is a potent antiviral agent against HBV and EBV and exhibits low cytotoxicity. Other specific examples of active compounds include N.sub.1 -(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-ethyluracil, N.sub.1 -(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-iodocytosine), and N.sub.1 -(2'-deoxy-2'-fluoro-.beta.-L-arabinofuranosyl)-5-iodouracil.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 10 USPATFULL on STN
AN 97:123193 USPATFULL
TI Non-invasive imaging of gene transfer
IN Blasberg, Ronald G., Riverside, CT, United States
Tjuvajev, Juri, Brooklyn, NY, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 5703056 19971230
AI US 1995-404513 19950315 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Low, Christopher S.F.
LREP White, John P.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 2015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention provides a method of detecting gene transfer to and expression in a target tissue of a host subject comprising: (a) administering to the host subject a transfer vector containing a marker gene not naturally present in the host and nontoxic to the host, wherein

the transfer vector transfects cells of the target tissue, under conditions such that the marker gene is expressed in transfected cells of the target tissue, thereby generating a marker gene product; (b) administering to the host subject a labelled marker substrate which is not metabolized by non-transfected cells, under conditions such that the marker substrate is metabolized by the marker gene product of step (a) to produce a labelled marker metabolite which is substantially retained in the transfected cells throughout a time-period sufficient for imaging the labelled marker metabolite; and (c) imaging the labelled marker metabolite, thereby detecting gene transfer to and expression in the target tissue. The subject invention provides a non-invasive, clinically applicable method for imaging gene transfer and expression which can be implemented using existing imaging techniques to monitor and evaluate in vivo gene therapy in **human** subjects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 10 USPATFULL on STN
AN 96:94568 USPATFULL
TI L-nucleosides for the treatment of epstein-bar virus
IN Chu, Chung K., Athens, GA, United States
Cheng, Yung-Chi, Woodbridge, CT, United States
Pai, Balakrishna S., New Haven, CT, United States
Yao, Gang-Oing, Guilford, CT, United States
PA University of GA Research Foundation, Athens, GA, United States (U.S. corporation)
Yale University, New Haven, CT, United States (U.S. corporation)
PI US 5565438 19961015
AI US 1995-466274 19950606 (8)
RLI Continuation of Ser. No. US 1994-189070, filed on 28 Jan 1994
DT Utility
FS Granted
EXNAM Primary Examiner: Wilson, James O.
LREP Zalesky, Cheryl K.Kilpatrick & Cody
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1317
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment of a **human** infected with EBV that includes administering an EBV-treatment amount of an L-nucleoside of the formula: ##STR1## wherein R is 5-methyluracil, and R' is hydrogen, acyl, alkyl or a monophosphate, diphosphate or triphosphate ester, or its pharmaceutically acceptable salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 10 USPATFULL on STN
AN 93:78770 USPATFULL
TI Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
IN Fox, Jack J., White Plains, NY, United States
Watanabe, Kyoichi A., Portchester, NY, United States
Lopez, Carlos, Carmel, IN, United States
Trepo, Christian G., Bran, France
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
Institut National de la Sante et de la Recherche Medicale, Paris, France (non-U.S. government)
PI US 5246924 19930921
AI US 1991-700334 19910506 (7)
RLI Continuation of Ser. No. US 1989-318602, filed on 3 Mar 1989, now

09567863

abandoned which is a continuation-in-part of Ser. No. US 1987-92446, filed on 3 Sep 1987, now abandoned
PRAI CA 1988-576381 19880902
DT Utility
FS Granted
EXNAM Primary Examiner: Brown, Johnnie R.; Assistant Examiner: Wilson, James O.
LREP White, John P.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1068
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition for, and a method of, treating a hepatitis viral infection in a subject using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil [FEAU].

CAS INDEXING IS AVAILABLE FOR THIS PATENT.